| Steqeyma |
761338 |
003 |
351(k) Interchangeable |
ustekinumab-stba |
Injection |
Intravenous |
130MG/26ML (5MG/ML) |
Single-Dose Vial |
2024/12/17
|
CELLTRION, Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Unloxcyt |
761297 |
001 |
351(a) |
cosibelimab-ipdl |
Injection |
Intravenous |
300MG/5ML (60MG/ML) |
Single-Dose Vial |
2024/12/13
|
Checkpoint Therapeutics, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Bizengri |
761352 |
001 |
351(a) |
zenocutuzumab-zbco |
Injection |
Intravenous |
375MG/18.75ML (20MG/ML) |
Single-Dose Vial |
2024/12/04
|
Merus NV |
Rx |
Licensed |
N/A |
N/A |
| Jivi |
125661 |
005 |
351(a) |
Antihemophilic factor (recombinant), PEGylated-aucl |
For Injection |
Intravenous |
4000IU |
Single-Dose Vial |
2024/12/02
|
Bayer HealthCare LLC |
Rx |
Licensed |
N/A |
N/A |
| Yesintek |
761406 |
001 |
351(k) Interchangeable |
ustekinumab-kfce |
Injection |
Subcutaneous |
45MG/0.5ML |
Single-Dose Vial |
2024/11/29
|
Biocon Biologics Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Yesintek |
761406 |
002 |
351(k) Interchangeable |
ustekinumab-kfce |
Injection |
Subcutaneous |
45MG/0.5ML |
Pre-Filled Syringe |
2024/11/29
|
Biocon Biologics Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Yesintek |
761406 |
003 |
351(k) Interchangeable |
ustekinumab-kfce |
Injection |
Subcutaneous |
90MG/ML |
Pre-Filled Syringe |
2024/11/29
|
Biocon Biologics Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Yesintek |
761406 |
004 |
351(k) Interchangeable |
ustekinumab-kfce |
Injection |
Intravenous |
130MG/26ML (5MG/ML) |
Single-Dose Vial |
2024/11/29
|
Biocon Biologics Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| regenecyte |
125764 |
001 |
351(a) |
HPC, Cord Blood |
Injection |
Intravenous |
>/=1.25x10E6 VIABLE CD34+ CELLS/UNIT IN >/=9x10E8 TNCs/UNIT |
Bag |
2024/11/21
|
StemCyte, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Ziihera |
761416 |
001 |
351(a) |
zanidatamab-hrii |
For Injection |
Intravenous |
300MG |
Single-Dose Vial |
2024/11/20
|
Jazz Pharmaceuticals Ireland Limited |
Rx |
Licensed |
N/A |
N/A |
| KEBILIDI |
125722 |
001 |
351(a) |
eladocagene exuparvovec-tneq |
Suspension |
Intraputaminal |
5.6x10^11VG/ML |
Single-Dose Vial |
2024/11/13
|
PTC Therapeutics |
Rx |
Licensed |
N/A |
N/A |
| Aucatzyl |
125813 |
001 |
351(a) |
Obecabtagene autoleucel |
Suspension |
Intravenous |
410 × 10^6CAR+ T CELLS TOTAL; DELIVERED AS A SPLIT DOSE IN 3-5 BAGS ON DAY 1 & 10 |
Bag |
2024/11/08
|
Autolus, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Selarsdi |
761343 |
003 |
351(k) Interchangeable |
ustekinumab-aekn |
Injection |
Intravenous |
130MG/26ML (5MG/ML) |
Single-Dose Vial |
2024/10/18
|
Alvotech USA Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Vyloy |
761365 |
001 |
351(a) |
zolbetuximab-clzb |
Injection |
Intravenous |
100MG |
Single-Dose Vial |
2024/10/18
|
Astellas Pharma US, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Bimzelx |
761151 |
003 |
351(a) |
bimekizumab-bkzx |
Injection |
Subcutaneous |
320MG/2ML (160MG/2ML) |
Pre-Filled Syringe |
2024/10/11
|
UCB, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Bimzelx |
761151 |
004 |
351(a) |
bimekizumab-bkzx |
Injection |
Subcutaneous |
320MG/2ML (160MG/2ML) |
Autoinjector |
2024/10/11
|
UCB, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Hympavzi |
761369 |
001 |
351(a) |
marstacimab-hncq |
Injection |
Subcutaneous |
150MG/ML |
Pre-Filled Syringe |
2024/10/11
|
Pfizer Inc. |
Rx |
Licensed |
N/A |
N/A |
| Hympavzi |
761369 |
002 |
351(a) |
marstacimab-hncq |
Injection |
Subcutaneous |
150MG/ML |
Autoinjector |
2024/10/11
|
Pfizer Inc. |
Rx |
Licensed |
N/A |
N/A |
| Imuldosa |
761364 |
001 |
351(k) Biosimilar |
ustekinumab-srlf |
Injection |
Subcutaneous |
45MG/0.5ML |
Pre-Filled Syringe |
2024/10/10
|
Accord BioPharma Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Imuldosa |
761364 |
002 |
351(k) Biosimilar |
ustekinumab-srlf |
Injection |
Subcutaneous |
90MG/ML |
Pre-Filled Syringe |
2024/10/10
|
Accord BioPharma Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |